Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa)
- PMID: 363104
- DOI: 10.1001/archneur.1978.00500360011002
Treatment of parkinsonism with N-n-propyl norapomorphine and levodopa (with or without carbidopa)
Abstract
The effects of the concomitant administration of N-n-propyl norapomorphine (NPA) and levodopa, with and without carbidopa, were studied in 12 patients with unsatisfactory symptom control. Double-blind evaluation of the effects of NPA with suboptimal doses of levodopa or levodopa plus carbidopa (Sinemet) showed a mean overall improvement of 44% (20% to 74%) in nine patients and improvement of the "on-off" effect in five. Dyskinesia diminished in some patients after diminution of basal medication. In three patients, plasma dopa and growth hormone patterns did not differ substantially with and without NPA. The magnitude and timing of the therapeutic and side effects did not correlate with the pattern of growth hormone secretion, which suggests that this hormone might not be instrumental in the induction of these effects. N-n-propyl norapomorphine is a useful adjunct in the long-term management of patients with unsatisfactory response to levodopa.
Similar articles
-
L-dopa and carbidopa (sinemet) in the management of parkinsonism.Postgrad Med J. 1975 Sep;51(599):619-21. doi: 10.1136/pgmj.51.599.619. Postgrad Med J. 1975. PMID: 1105500 Free PMC article. Clinical Trial.
-
Treatment of "on-off effect" with a dopa decarboxylase inhibitor.Arch Neurol. 1975 Aug;32(8):560-3. doi: 10.1001/archneur.1975.00490500080010. Arch Neurol. 1975. PMID: 1156214 Clinical Trial.
-
Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.N Engl J Med. 1976 Mar 11;294(11):567-72. doi: 10.1056/NEJM197603112941101. N Engl J Med. 1976. PMID: 1107835 Clinical Trial.
-
Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.Neurology. 1992 Jan;42(1 Suppl 1):51-6; discussion 57-60. Neurology. 1992. PMID: 1549202 Review.
-
Individualization of levodopa therapy.Med Clin North Am. 1974 Sep;58(5):1071-81. doi: 10.1016/s0025-7125(16)32103-4. Med Clin North Am. 1974. PMID: 4609364 Review. No abstract available.
Cited by
-
Degradation of Tyrosine Hydroxylase by the Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease and Dopa-Responsive Dystonia.Int J Mol Sci. 2020 May 27;21(11):3779. doi: 10.3390/ijms21113779. Int J Mol Sci. 2020. PMID: 32471089 Free PMC article. Review.
-
Potential of transdermal drug delivery in Parkinson's disease.Drugs Aging. 2002;19(8):561-70. doi: 10.2165/00002512-200219080-00002. Drugs Aging. 2002. PMID: 12207550 Review.
-
Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait.J Neurophysiol. 2010 Mar;103(3):1478-89. doi: 10.1152/jn.00664.2009. Epub 2009 Dec 30. J Neurophysiol. 2010. PMID: 20042701 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources